ArticleMalaria journal2025
Evaluation of seasonal malaria chemoprevention implementation in the Upper East region of Northern Ghana.
Article in Malaria journal, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Household characteristics, water, sanitation and hygiene (WASH) and malaria prevalence among children aged 6-59 months in Ghana: an analysis of the 2022 Ghana Demographic and Health Survey.Malaria journal · 2026Article
- Malaria incidence rose following the introduction of neonicotinoid-based IRS in selected districts in northern Ghana: An observational analysis.PLOS global public health · 2026Article
- Rethinking a hybrid malaria chemoprevention delivery strategy for children in sub-perennial settings: a modelling study integrating age- and seasonally-targeted delivery.Malaria journal · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundGhana adopted the WHO-recommended Seasonal Malaria Chemoprevention (SMC) in 2016 following a pilot study as a vital strategy for malaria control. SMC is the intermittent administration of a preventive and curative dose of anti-malarial medicine (Sulfadoxine-Pyrimetamine + Amodiaquine) during four months of the malaria season. This study monitored the implementation of SMC to ensure the intervention is achieving its target.
methodsThis was a longitudinal study in four administrative districts of the Upper East Region of Ghana. Children aged between 3 and 59 months were sampled and followed up one week after each cycle of SMC dosing to complete a questionnaire. SMC status was determined through the caregiver's report and child welfare cards, if available. Caregivers were asked if the participant had been treated for malaria since the last cycle. Simple and multiple logistic regressions were employed to determine associations between SMC adherence and the independent variables, with all results interpreted at a 95% confidence level (CI).
resultsThis study reported an average SMC coverage of 87% (CI: 86.7-89.5) per cycle with a 2% dropout after the first cycle. SMC adherence rate remained above 82% (CI: 1.4-2.5), with malaria incidence decreasing in those who received all four doses of SMC compared to partial recipients. Health system/programme (49%) and patient related factors (33%) were the main reasons reported for non-adherence. Significant predictors of adherence were household size (aOR = 1.04, 95% CI 1.01-1.08), sleeping under bed nets (aOR = 1.88, 95% CI 1.44-2.48), and indoor residual spraying (IRS) presence (aOR = 0.83, 95% CI 0.69-1.99).
conclusionDespite achieving an average coverage of 87% per cycle, it falls short of the national target of 90%. Notable reasons for drop-outs and non-adherence were, the caregiver being unavailable during the distribution, highlighting the need for diversified approaches in SMC campaigns to enhance coverage, and adherence, and maximize intervention benefits.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.